{"created":"2015-05-14T02:31:49+00:00","modified":"2015-05-15T13:28:11+00:00","valid":{"from":"2013-04-16T09:17:45+00:00","to":"3013-04-16T09:17:45+00:00"},"hreflang":"en","contentencoded":"<div class=\"barn-cleaned\"><p>Patent protection for the painkiller OxyContin expires today. That means generic drug manufacturers hope to soon grab a chunk of the nearly $3 billion market. But first, the FDA must give its blessing -- but right now, that's far from certain.</p>\n<p>OxyContin is one of the most dangerous and widely abused drugs available. And the FDA is hesitant is to flood the market with a painkiller that's easily abused. So no matter how anxious generic drug makers are, RBC Capital Markets analyst Shibani Malhotra says the firms may have to wait.</p>\n<p>\"Every single company executive that we've spoken to believes that the market is going to have to move to tamper resistant products,\" Malhotra says.&nbsp;</p>\n<p>The FDA may require tamper-resistant drugs, like a pill that's impossible to crush into powder.</p>\n<p>But Justin Collishaw, with Frost &amp; Sullivan, says requiring tamper-resistant safeguards makes it harder for generics to get into the game.&nbsp;</p>\n<p>\"Do I think that a generic manufacturer would develop their own tamper resistant formulation? The margins are not there,\" Collishaw says.</p>\n<p>Industry observers believe the issue is so thorny, the FDA may remain silent over the coming weeks. &nbsp;</p></div>","itags":["1042bc1e245c0a0532cfe8c222888f1b","Marketplace","Marketplace Morning Report for Tuesday, April 16, 2013","PMP:Marketplace_PMP","Marketplace Morning Report"],"contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p>Patent protection for the painkiller OxyContin expires today. That means generic drug manufacturers hope to soon grab a chunk of the nearly $3 billion market. But first, the FDA must give its blessing -- but right now, that&apos;s far from certain.</p>\"},{\"content\":\"<p>OxyContin is one of the most dangerous and widely abused drugs available. And the FDA is hesitant is to flood the market with a painkiller that&apos;s easily abused. So no matter how anxious generic drug makers are, RBC Capital Markets analyst Shibani Malhotra says the firms may have to wait.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>&quot;Every single company executive that we&apos;ve spoken to believes that the market is going to have to move to tamper resistant products,&quot; Malhotra says. </p>\"},{\"type\":\"text/html\",\"content\":\"<p>The FDA may require tamper-resistant drugs, like a pill that&apos;s impossible to crush into powder.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>But Justin Collishaw, with Frost &amp; Sullivan, says requiring tamper-resistant safeguards makes it harder for generics to get into the game. </p>\"},{\"type\":\"text/html\",\"content\":\"<p>&quot;Do I think that a generic manufacturer would develop their own tamper resistant formulation? The margins are not there,&quot; Collishaw says.</p>\"},{\"content\":\"<p>Industry observers believe the issue is so thorny, the FDA may remain silent over the coming weeks.  </p>\",\"type\":\"text/html\"}]","title":"OxyContin's waiting game: Generic drug makers salivate while the FDA wants safer pills","description":"OxyContin is supposed to come off patent and generic drug makers are excited. But, the FDA may put a stop to it all to wait for safer pills.","guid":"1042bc1e-245c-40a0-832c-e8c222888f1b","tags":["APM","FDA","Health Care","Purdue Pharma","generic drugs","oxycontin"],"byline":"D Gorenstein","teaser":"OxyContin is supposed to come off patent and generic drug makers are excited. But, the FDA may put a stop to it all to wait for safer pills.","published":"2013-04-16T09:17:45+00:00","audio":[{"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/678211_0.jpg?itok=yXv4Pxqj","meta":{"width":"610","height":"340","crop":"primary"},"type":"image/jpeg"},{"meta":{"api":{"type":"application/json","href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2013/04/16/marketplace_segment04_20130416"},"duration_hms":"00:01:22","duration":82},"href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2013/04/16/marketplace_segment04_20130416_64.mp3","format":"MP3","type":"audio/mpeg"}]}